A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer

阿替唑单抗 医学 肿瘤科 不利影响 内科学 临床研究阶段 癌症 免疫疗法 临床试验 泌尿科 彭布罗利珠单抗
作者
Randy F. Sweis,Gurkamal Chatta,Rohit K. Jain,Helen Moon,Scott E. Delacroix,Alana Fang,Leonard D’Amico,Angela Shaulov Kask,Martin A. Cheever,Steven P. Fling,Elad Sharon,Andreanne M. Lacroix,Judith C. Kaiser,Russell K. Pachynski,Evan Y. Yu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-24-1728
摘要

Abstract Purpose: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (CITN-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses. Patients and Methods: Patients with urothelial cancer following platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines. Results: CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities (DLTs), and lower grade 3-4 treatment-related adverse events (TRAEs) compared to atezolizumab. The ORR was 26.3% for the combination versus 23.8% for atezolizumab alone (p = 0.428). The complete response (CR) rate was 10.5% for the combination versus 4.8% for monotherapy. Three patients on the combination had responses >21 months versus one with monotherapy. CD4+ and CD8+ T lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cell (Tscm) cells. Responding patients had elevated baseline CCL4 and decreased VEGF-A and TNF. Conclusions: Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the CR rate, and durable responses exceeding 2 years, however, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CC完成签到 ,获得积分10
刚刚
1秒前
罗大壮发布了新的文献求助10
1秒前
walu发布了新的文献求助10
1秒前
HHHHH完成签到,获得积分10
1秒前
2秒前
lalala发布了新的文献求助10
3秒前
pluto应助郭小胖14采纳,获得10
3秒前
3秒前
3秒前
CipherSage应助菠萝采纳,获得10
3秒前
cnm完成签到,获得积分20
4秒前
mo完成签到,获得积分10
4秒前
静俏发布了新的文献求助10
4秒前
111发布了新的文献求助10
4秒前
4秒前
传奇3应助QingSun1采纳,获得10
4秒前
小米饭完成签到,获得积分10
4秒前
量子星尘发布了新的文献求助10
5秒前
勤劳小海豚完成签到,获得积分10
6秒前
Wu关闭了Wu文献求助
6秒前
6秒前
zzk发布了新的文献求助10
6秒前
爽哥发布了新的文献求助30
6秒前
听话的不乐完成签到,获得积分10
7秒前
langjiaqi关注了科研通微信公众号
7秒前
7秒前
淡淡的襄完成签到,获得积分10
7秒前
msy发布了新的文献求助10
7秒前
天天快乐应助魅雪霓采纳,获得10
8秒前
szw发布了新的文献求助10
8秒前
wuhuanga发布了新的文献求助10
8秒前
玫瑰遇上奶油完成签到,获得积分10
8秒前
9秒前
奶冻发布了新的文献求助10
9秒前
Jasper应助WillianLinnn采纳,获得10
9秒前
高挑的安白完成签到 ,获得积分10
10秒前
10秒前
乐乐应助科研通管家采纳,获得10
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971091
求助须知:如何正确求助?哪些是违规求助? 3515797
关于积分的说明 11179488
捐赠科研通 3250872
什么是DOI,文献DOI怎么找? 1795536
邀请新用户注册赠送积分活动 875891
科研通“疑难数据库(出版商)”最低求助积分说明 805207